Clinical Trials Logo

Severe Hypertriglyceridemia clinical trials

View clinical trials related to Severe Hypertriglyceridemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05355402 Completed - Clinical trials for Hypertriglyceridemia

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

Start date: May 9, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the percentage of participants who achieve different thresholds in fasting TG. Another objective is to evaluate the effect of olezarsen on percent change in fasting apolipoprotein C-III (apoC-III), very low-density lipoprotein cholesterol (VLDL-C), remnant cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, total cholesterol (TC), apolipoprotein B (apoB), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein A-1 (apoA-1).

NCT ID: NCT04720534 Completed - Clinical trials for Severe Hypertriglyceridemia

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

SHASTA-2
Start date: May 31, 2021
Phase: Phase 2
Study type: Interventional

The purpose of AROAPOC3-2001 is to evaluate the efficacy and safety of ARO-APOC3 in participants with severe hypertriglyceridemia. Participants will receive 2 subcutaneous injections of ARO-APOC3.

NCT ID: NCT04541186 Completed - Clinical trials for Severe Hypertriglyceridemia

Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia

Start date: September 1, 2020
Phase: Phase 2
Study type: Interventional

This study is designed to assess the efficacy, safety, and tolerability of different doses and dose regimens (QW or every 2 weeks [Q2W]), subcutaneous (SC) dosing of BIO89-100 compared to placebo in subjects with Severe Hypertriglyceridemia (SHTG).

NCT ID: NCT03011450 Completed - Clinical trials for Severe Hypertriglyceridemia

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

Start date: November 26, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients With Fasting High Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Mild or Moderate Renal Impairment.

NCT ID: NCT03001817 Completed - Clinical trials for Severe Hypertriglyceridemia

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

Start date: November 28, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients with fasting high triglyceride levels ≥500 mg/dL and <2000 mg/dL and normal renal function.

NCT ID: NCT02944383 Completed - Clinical trials for Severe Hypertriglyceridemia

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia

INDIGO-1
Start date: December 2016
Phase: Phase 2
Study type: Interventional

A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)

NCT ID: NCT02189252 Completed - Clinical trials for Severe Hypertriglyceridemia

An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis

ECLIPSEIV
Start date: October 2014
Phase: Phase 1
Study type: Interventional

This is a randomized, open-label crossover study. The primary objective of this study is to compare the relative bioavailability of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and the ethyl esters of EPA and DHA in plasma from a single 2 g or 4 g dose of Epanova® or 4 g Lovaza®.

NCT ID: NCT01242527 Completed - Clinical trials for Severe Hypertriglyceridemia

Epanova® for Lowering Very High Triglycerides

EVOLVE
Start date: January 2011
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.

NCT ID: NCT01208961 Completed - Clinical trials for Severe Hypertriglyceridemia

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

ECLIPSE
Start date: September 2010
Phase: Phase 2
Study type: Interventional

The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat consumption.